Enterprise Unit
Licensing and Partnering Opportunities
Currently there are a number of partnering and licensing opportunities and any member of the Enterprise Unit would be pleased to review these with potential commercial collaborators.
Platforms/Software Applications
View our Portfolio of Licensing and Partnering Opportunities
Therapeutics
B-RAF Inhibitors
Wellcome Trust licensing opportunity.
Principal Scientists: Professor Richard Marais and Professor Caroline Springer
Novel inhibitors of enzyme B-RAF. Four chemical series, three pre-clinical candidates. Proof of concept demonstrated in vivo. Compounds orally active in melanoma and colorectal xenograft models. Compounds demonstrate a range of selectivity profiles.
For further information contact Angela Kukula or download the PDF flyer
Lysyl Oxidase
Wellcome Trust collaboration and licensing opportunity.
Principal Scientist: Professor Caroline Springer
Lysyl oxidase (LOX) is an extracellular enzyme responsible for crosslinking of collagen and elastin. LOX expression is regulated by hypoxia inducible factors (HIFs) and LOX is upregulated in hypoxic tumours. Secreted LOX leads to invasion and metastases and hence inhibitors of LOX should prevent tumour progression and metastases.
For more information contact Angela Kukula or download the PDF flyer.
Targets
HDAC9, A Novel Histone Deacetylase
ICR collaboration and licensing opportunity.
Principal Scientists: Dr Arthur Zelent
Characterisation of a novel HDAC associated with cancer. Potential drug target and diagnostic marker.
For further information contact Paul Carnochan or download the PDF flyer
Glypican-5, A Novel Cancer Target
ICR collaboration and licensing opportunity.
Principal Scientists: Dr Janet Shipley
GPC5 has been identified as a potential therapeutic target in soft tissue sarcoma, breast carcinoma, lung carcinoma, lymphoma, medulloblastoma and glioblastoma. This target is amenable to antibody mediated therapies. It also has potential as a biomarker.
For further information contact Jonathan Beecn or download the PDF flyer.
Diagnostic Biomarkers
Monoclonal Antibodies against Cerb-B2
ICR collaboration and licensing opportunity.
Principal Scientists: Dr Steve Hobbs and Dr Suzanne Eccles
A panel of rat anti Cerb-B2 antibodies has been developed and is now available for diagnostic and therapeutic applications. Extensive pre-clinical evaluation has been completed.
For further information contact Jonathan Beech or download the PDF flyer
Monoclonal Antibodies against EGFR
ICR licensing opportunity.
Principal Scientist: Dr Suzanne Eccles
A set of rat monoclonal anti EGFR antibodies has been developed and are available for diagnostic and therapeutic applications. Extensive preclinical characterisation completed. One antibody has completed Phase 1B Clinical trials.
For further information contact Jonathan Beech or download the PDF flyer
Anti-KSR Monoclonal Antibody
Cancer Research Technology licensing opportunity.
Principal Scientist: Professor Richard Marais
Clone name: MINT/1/4 Host species: rat Ig isotype: IgG2a Immunogen: Full length mouse KSR-GST fusion Protein Antibody available for licensing.
For more information contact Enterprise Unit
Devices
Device for Tissue Processing
ICR licensing opportunity.
Principal Scientists: Dr Sameer Jhavar and Dr Stefan Reinsberg
Laboratory tool for rapid and accurate slicing of fresh tissue samples, providing for co-alignment with tissue imaging.
For more information contact Jennifer Hodgson or download the PDF flyer
Endocovitary Coil for 3T-MRI l
ICR collaboration and licensing opportunity
Principal Scientist: Prof Nandita de Souza
Endocovitary coil for improved 3T-MR diagnostic imaging of the cervix
For more information contact Paul Carnochan
Method and Cutter for Tissue Microarrays
ICR exclusive commercialisation rights
Principal Scientist: Prof Colin Cooper
Method for the production of tissue microarrys from needle biopsies allowing high sample density and laboratory tool for precise cutting of samples.
For more information contact Paul Carnochan or download the PDF flyer
Platforms / Software Applications
4D Orthogonal Display Tool
ICR collaboration & licence opportunity
Principal Scientists: Professor Martin Leach
Software tool for rapid identification of tissue movement artifacts during analysis of dynamic MRI data sets.
For more information contact Paul Carnochan or download the PDF flyer
Dosimetry for Radionuclide Treatment
ICR collaboration and licensing opportunity.
Principle Scientist: Dr Glenn Flux
Dosimetry Software package for image analysis and dosimetry applied to targeted radionuclide therapy.
For more information contact Paul Carnochan or download the PDF flyer
MRI Distortion Correction
ICR collaboration and licensing opportunity.
Principal Scientists: Dr Simon Doran
Algorithms for evaluation and correction of geometric distortion in MR images, for applications including radiotherapy treatment planning.
For more information contact Paul Carnochan or download to PDF flyer
3D Kinetic Volume Rendering Tool for MRI
ICR collaboration and licensing opportunity.
Principle Scientist: Professor Martin Leach
Software to enable separate display of MIPs derived from different phases of MR contrast capable kinetics.
For more information contact Paul Carnochan
View our Portfolio of Licensing and Partnering Opportunities
